The
“It was a relatively straightforward decision,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, at a news conference. The vaccine generated a strong immune response, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.